Drug patents arent cracking because the law changed overnight. Theyre cracking because attackers know where to swing first.
Thats the real lesson behind a deceptively simple idea: device patents often exposeearlythe weakest wall in a drug patent port…
Why Device Patents Crack First: The Weakest Wall in Your Drug’s Patent Fortress Read Post »
The salt-change trap: When a new patent buys you nothing
Theres a quiet strategy playing out across generic marketsone that looks like innovation, sounds like progress, and often functions like delay. It doesnt arrive with fireworks. It arrives with a …
The Salt Change Trap: When a New Patent Buys You Nothing Read Post »
Pediatric exclusivity was supposed to be a safeguard: an extra six months of market protection to encourage drug developers to study children.
But in practice, the six-month fuse is too often a liabilitynot a shield.
Heres the uncomfortable reality: …
The Six-Month Fuse: Why Pediatric Exclusivity Is a Liability, Not a Shield Read Post »
ð¨ Why Bausch Healths latest patent fight matters (even if you dont follow pharma litigation).
In pharma, the headline moment often isnt the drugits the right to sell the drug. And in the case highlighted by DrugPatentWatch, Bausch Health Companies I…
BAUSCH HEALTH COMPANIES INC. v. SUN PHARMACEUTICAL INDUSTRIES LTD. Read Post »
Exelixis v. Intas: Patents Dont Just Decide Drug FuturesThey Define Timelines, Incentives, and Who Can Afford to Wait.
Heres why this case matters beyond the courtroom.
The agitation:
When we talk about patent battles, its easy to imagine a binary outc…
Amneal vs. Alembic: The Patent Fight Thats Really About Time
In the pharmaceutical industry, the most valuable commodity isnt always the moleculeits the clock.
Thats the subtext behind Amneal Pharmaceuticals, LLC v. Alembic Pharmaceuticals, Ltd., a dis…
Amneal Pharmaceuticals LLC v. Alembic Pharmaceuticals Ltd. Read Post »
Big pharmas routine patent fight is never routine. Its a strategy memo in disguise.
Thats the takeaway from Exelixis, Inc. v. Handa Pharmaceuticals, Inc.a case that may look narrow on the surface (a specific patent, a specific counterparty), but that…
Takeda vs. Sun Pharma: The Hidden Economics of Patent Litigation (and why investors should care)
Patent lawsuits are often framed as courtroom dramascomplex claims, expert testimony, and a slow grind toward a verdict. But beneath the legal headlines is…
TAKEDA PHARMACEUTICALS U.S.A., INC. v. SUN PHARMACEUTICAL INDUSTRIES LTD. Read Post »
Pharma innovation isnt just about what gets inventedits about what gets protected.
Thats the lens investors and industry watchers should use when following the latest developments highlighted in Azuirty Pharmaceuticals, Inc. v. Aurobindo Pharma Limited…
Azurity Pharmaceuticals, Inc. v. Aurobindo Pharma Limited Read Post »
Vertex Pharmaceuticals v. Squires is one of those rare moments where patent law, valuation math, and clinical reality collideand where the market often has to reprice faster than it can read.
Why this matters now: In the pharmaceutical industry, litiga…
Get new actionable insights and updates from BiotechBlog
